Amgen (AMG) Stock Forecast & Price Target

1 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

AMG Analyst Ratings

Moderate Buy

9 Buy

11 Hold

2 Sell

Based on 22 analysts giving stock ratings to

Amgen

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

AMG Stock 12 Month Forecast

Average Price Target

CHF310.56

▲(4.54% Upside)

Based on 22 Wall Street analysts offering 12 month price targets for Amgen in the last 3 months. The average price target is CHF310.56 with a high forecast of CHF365.55 and a low forecast of CHF186.01. The average price target represents a 4.54% change from the last price of CHF297.07.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"185":"CHF185","366":"CHF366","230.25":"CHF230.3","275.5":"CHF275.5","320.75":"CHF320.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":365.5526496,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">CHF365.55</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":310.5580032,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">CHF310.56</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":186.011304,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">CHF186.01</span>\n  </div></div>","useHTML":true}}],"tickPositions":[185,230.25,275.5,320.75,366],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,322.69,325.9871268923077,329.2842537846154,332.58138067692306,335.87850756923075,339.17563446153844,342.4727613538462,345.76988824615387,349.06701513846156,352.36414203076924,355.66126892307693,358.9583958153846,362.2555227076923,{"y":365.5526496,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,322.69,321.75676947692307,320.82353895384614,319.8903084307692,318.9570779076923,318.02384738461535,317.0906168615384,316.15738633846155,315.2241558153846,314.2909252923077,313.35769476923076,312.42446424615383,311.4912337230769,{"y":310.5580032,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,322.69,312.1762541538462,301.6625083076923,291.14876246153847,280.63501661538464,270.12127076923076,259.60752492307694,249.09377907692308,238.58003323076923,228.06628738461538,217.55254153846153,207.0387956923077,196.52504984615385,{"y":186.011304,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":226.357,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 35,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 4</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 24,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 32,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 27,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 20, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":226.357,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 26,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 27, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":289.909,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 22, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":322.69,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 21, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 3</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price TargetCHF365.55

Average Price TargetCHF310.56

Lowest Price TargetCHF186.01

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Geoff Meacham

Citi

CHF279.02→CHF327.54

Hold

10.26%

Upside

Reiterated

08/10/26

Citi Keeps Their Hold Rating on Amgen (AMGN)

Vamil Divan

Guggenheim

CHF277.4→CHF313.79

Hold

5.63%

Upside

Reiterated

08/07/26

Amgen price target raised to $388 from $343 at GuggenheimAmgen price target raised to $388 from $343 at Guggenheim

Chris Schott

J.P. Morgan

CHF283.06

Hold

-4.72%

Downside

Reiterated

08/06/26

J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)

Yaron Werber

TD Cowen

CHF339.67→CHF365.55

Buy

23.05%

Upside

Reiterated

08/05/26

TD Cowen Sticks to Its Buy Rating for Amgen (AMGN)

Jay Olson

Oppenheimer

CHF323.5→CHF363.94

Buy

22.51%

Upside

Reiterated

08/05/26

Amgen price target raised to $450 from $400 at OppenheimerAmgen price target raised to $450 from $400 at Oppenheimer

David Amsellem

Piper Sandler

CHF345.33

Buy

16.25%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Exagen (NASDAQ: XGN), Amgen (NASDAQ: AMGN) and Arvinas Holding Company (NASDAQ: ARVN)

Gregory Renza

Truist Financial

CHF274.97→CHF292.77

Hold

-1.45%

Downside

Reiterated

08/05/26

Truist Financial Reaffirms Their Hold Rating on Amgen (AMGN)

Terence Flynn

Morgan Stanley

CHF269.31→CHF283.87

Hold

-4.44%

Downside

Assigned

08/05/26

Terence Flynn Reaffirms Hold on Amgen as Strong Q2 Results and 2026 Guidance Boost Outlook, Price Target Raised from $333 to $351

Evan Seigerman

BMO Capital

CHF323.5→CHF363.94

Buy

22.51%

Upside

Reiterated

08/05/26

Amgen price target raised to $450 from $400 at BMO CapitalAmgen price target raised to $450 from $400 at BMO Capital

Salveen Richter

Goldman Sachs

CHF345.33→CHF363.94

Buy

22.51%

Upside

Reiterated

08/05/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Eli Lilly & Co (LLY)

Courtney Breen

Bernstein

CHF270.93→CHF279.02

Hold

-6.08%

Downside

Reiterated

08/05/26

Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)

Tazeen Ahmad

Bank of America Securities

CHF252.33→CHF256.37

Sell

-13.70%

Downside

Reiterated

08/05/26

Amgen price target raised to $317 from $312 at BofAAmgen price target raised to $317 from $312 at BofA

Louise Chen

Scotiabank

CHF363.94

Buy

22.51%

Upside

Reiterated

08/05/26

Amgen (AMGN) Receives a Buy from Scotiabank

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/05/26

Analyst Maintains Buy on Amgen After Strong Q2 Beat, Raised Guidance and Multiple Late-Stage Pipeline Catalysts

Michael Yee

UBS

CHF339.67→CHF355.85

Buy

19.79%

Upside

Reiterated

08/05/26

UBS Keeps Their Buy Rating on Amgen (AMGN)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Geoff Meacham

Citi

CHF279.02→CHF327.54

Hold

10.26%

Upside

Reiterated

08/10/26

Citi Keeps Their Hold Rating on Amgen (AMGN)

Vamil Divan

Guggenheim

CHF277.4→CHF313.79

Hold

5.63%

Upside

Reiterated

08/07/26

Amgen price target raised to $388 from $343 at GuggenheimAmgen price target raised to $388 from $343 at Guggenheim

Chris Schott

J.P. Morgan

CHF283.06

Hold

-4.72%

Downside

Reiterated

08/06/26

J.P. Morgan Reaffirms Their Hold Rating on Amgen (AMGN)

Yaron Werber

TD Cowen

CHF339.67→CHF365.55

Buy

23.05%

Upside

Reiterated

08/05/26

TD Cowen Sticks to Its Buy Rating for Amgen (AMGN)

Jay Olson

Oppenheimer

CHF323.5→CHF363.94

Buy

22.51%

Upside

Reiterated

08/05/26

Amgen price target raised to $450 from $400 at OppenheimerAmgen price target raised to $450 from $400 at Oppenheimer

David Amsellem

Piper Sandler

CHF345.33

Buy

16.25%

Upside

Reiterated

08/05/26

Analysts Offer Insights on Healthcare Companies: Exagen (NASDAQ: XGN), Amgen (NASDAQ: AMGN) and Arvinas Holding Company (NASDAQ: ARVN)

Gregory Renza

Truist Financial

CHF274.97→CHF292.77

Hold

-1.45%

Downside

Reiterated

08/05/26

Truist Financial Reaffirms Their Hold Rating on Amgen (AMGN)

Terence Flynn

Morgan Stanley

CHF269.31→CHF283.87

Hold

-4.44%

Downside

Assigned

08/05/26

Terence Flynn Reaffirms Hold on Amgen as Strong Q2 Results and 2026 Guidance Boost Outlook, Price Target Raised from $333 to $351

Evan Seigerman

BMO Capital

CHF323.5→CHF363.94

Buy

22.51%

Upside

Reiterated

08/05/26

Amgen price target raised to $450 from $400 at BMO CapitalAmgen price target raised to $450 from $400 at BMO Capital

Salveen Richter

Goldman Sachs

CHF345.33→CHF363.94

Buy

22.51%

Upside

Reiterated

08/05/26

Analysts' Top Healthcare Picks: Amgen (AMGN), Eli Lilly & Co (LLY)

Courtney Breen

Bernstein

CHF270.93→CHF279.02

Hold

-6.08%

Downside

Reiterated

08/05/26

Bernstein Reaffirms Their Hold Rating on Amgen (AMGN)

Tazeen Ahmad

Bank of America Securities

CHF252.33→CHF256.37

Sell

-13.70%

Downside

Reiterated

08/05/26

Amgen price target raised to $317 from $312 at BofAAmgen price target raised to $317 from $312 at BofA

Louise Chen

Scotiabank

CHF363.94

Buy

22.51%

Upside

Reiterated

08/05/26

Amgen (AMGN) Receives a Buy from Scotiabank

Matt Phipps

William Blair

―

Buy

―

Reiterated

08/05/26

Analyst Maintains Buy on Amgen After Strong Q2 Beat, Raised Guidance and Multiple Late-Stage Pipeline Catalysts

Michael Yee

UBS

CHF339.67→CHF355.85

Buy

19.79%

Upside

Reiterated

08/05/26

UBS Keeps Their Buy Rating on Amgen (AMGN)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

AVBPArriVent BioPharma, Inc.

BTSGBrightSpring Health Services, Inc.

AMLXAmylyx Pharmaceuticals Inc

TNYATenaya Therapeutics

JBIOJade Biosciences

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Amgen

3 Months

David AmsellemPiper Sandler

Success Rate

14/19 ratings generated profit

Average Return

+6.13%

Copying David Amsellem's trades and holding each position for 3 Months would result in 73.68% of your transactions generating a profit, with an average return of +6.13% per trade.

1 Year

David AmsellemPiper Sandler

Success Rate

19/19 ratings generated profit

Average Return

+25.24%

Copying David Amsellem's trades and holding each position for 1 Year would result in 100.00% of your transactions generating a profit, with an average return of +25.24% per trade.

2 Years

David AmsellemPiper Sandler

Success Rate

19/19 ratings generated profit

Average Return

+33.72%

Copying David Amsellem's trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +33.72% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

AMG Analyst Recommendation Trends

Rating

Apr 26

May 26

Jun 26

Jul 26

Aug 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, AMG has received 18 Buy Ratings, 21 Hold Ratings, and 3 Sell Ratings. AMG average Analyst price target in the past 3 months is 310.56.

Each month's total comprises the sum of three months' worth of ratings.

AMG Financial Forecast

AMG Earnings Forecast

Next quarter’s earnings estimate for AMG is CHF4.70 with a range of CHF4.43 to CHF4.99. The previous quarter’s EPS was CHF5.09. AMG beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 58.33% of the time in the same period. In the last calendar year AMG has Performed in-line its overall industry.

AMG Sales Forecast

Next quarter’s sales forecast for AMG is CHF8.08B with a range of CHF7.74B to CHF8.31B. The previous quarter’s sales results were CHF8.14B. AMG beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 66.67% of the time in the same period. In the last calendar year AMG has Performed in-line its overall industry.

AMG Stock Forecast FAQ

What is CH:AMG’s average 12-month price target, according to analysts?

Based on analyst ratings, Amgen Inc’s 12-month average price target is 310.56.

What is CH:AMG’s upside potential, based on the analysts’ average price target?

Amgen Inc has 4.54% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Amgen Inc a Buy, Sell or Hold?

Amgen Inc has a consensus rating of Moderate Buy, which is based on 9 buy ratings, 11 hold ratings and 2 sell ratings.

What is Amgen Inc’s share price target?

The average share price target for Amgen Inc is 310.56. This is based on 22 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is CHF365.55 ,and the lowest forecast is CHF186.01. The average share price target represents 4.54% Increase from the current price of CHF297.07.

What do analysts say about Amgen Inc?

Amgen Inc’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 22 Wall Streets Analysts.

How can I buy shares of Amgen Inc?

To buy shares of CH:AMG, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Amgen (AMG) Stock Forecast & Price Target

AMG Analyst Ratings

AMG Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Amgen

AMG Analyst Recommendation Trends

AMG Financial Forecast

AMG Earnings Forecast

AMG Sales Forecast

AMG Stock Forecast FAQ

Detailed List of Analyst Forecasts